SCHEMBL17361925

SCHEMBL17361925

CN(c1cccc(C#N)c1)c1ccc2c(c1)CCC[C@H]2CNC(=O)OC(C)(C)C

nearest known ligand 0.60

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 19/20 0.60
KDM6B O15054 8/20 0.47
KDM4A O75164 1/20 0.47
KDM4B O94953 1/20 0.47
KDM4D Q6B0I6 1/20 0.47
KDM5B Q9UGL1 1/20 0.47
HTR6 P50406 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17361926 0.93 KDM4C (0.59) KDM4CKDM6BKDM4AKDM4BKDM4D
SCHEMBL17362072 0.89 KDM4C (0.57) KDM4CKDM6BKDM4AKDM4BKDM4D
SCHEMBL22744715 0.89 KDM4C (0.57) KDM4CKDM6BKDM4AKDM4BKDM4D
SCHEMBL21258052 0.87 KDM4C (0.68) KDM4CKDM6BKDM4AKDM4BKDM4D
SCHEMBL17361825 0.86 KDM4C (0.58) KDM4CKDM6BKDM4AKDM4BKDM4D
SCHEMBL17361516 0.85 KDM4C (0.56) KDM4CKDM6BKDM4AKDM4BKDM4D
SCHEMBL17361423 0.84 KDM4C (0.57) KDM4CKDM6BKDM4AKDM4BKDM4D
SCHEMBL17361451 0.84 KDM4C (0.57) KDM4CKDM6BKDM4AKDM4BKDM4D
SCHEMBL17361411 0.84 KDM4C (0.57) KDM4CKDM6BKDM4AKDM4BKDM4D
SCHEMBL17361427 0.84 KDM4C (0.61) KDM4CKDM6BKDM4AKDM4BKDM4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111909083-B Inhibitors of histone demethylase 赛尔基因昆蒂赛尔研究公司 2023-08-15 CN disclosed
EP-3160952-B1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RES INC (US) 2020-12-02 EP disclosed
EP-3160952-B1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RES INC (US) 2020-12-02 EP disclosed
EP-3741749-A1 HISTONE DEMETHYLASE INHIBITORS Celgene Quanticel Research, Inc. (US) 2020-11-25 EP disclosed
EP-3738960-A1 HISTONE DEMETHYLASE INHIBITORS Celgene Quanticel Research, Inc. (US) 2020-11-18 EP disclosed
EP-3738960-A1 HISTONE DEMETHYLASE INHIBITORS Celgene Quanticel Research, Inc. (US) 2020-11-18 EP disclosed
CN-111909083-A Histone demethylase inhibitors 赛尔基因昆蒂赛尔研究公司 2020-11-10 CN disclosed
CN-106660982-B Histone demethylase inhibitors 赛尔基因昆蒂赛尔研究公司 2020-09-08 CN disclosed
US-10385047-B2 Histone demethylase inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2019-08-20 US disclosed
US-10106534-B2 Histone demethylase inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2018-10-23 US disclosed
US-20160107995-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. 2016-04-21 US disclosed
US-20160107995-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. 2016-04-21 US disclosed
US-20160107995-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. 2016-04-21 US disclosed
US-9242968-B2 Histone demethylase inhibitors Quanticel Pharmaceuticals, Inc. (US) 2016-01-26 US disclosed
US-9242968-B2 Histone demethylase inhibitors Quanticel Pharmaceuticals, Inc. (US) 2016-01-26 US disclosed
US-9242968-B2 Histone demethylase inhibitors Quanticel Pharmaceuticals, Inc. (US) 2016-01-26 US disclosed
US-20150376169-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. 2015-12-31 US disclosed
US-20150376169-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. 2015-12-31 US disclosed
US-20150376169-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. 2015-12-31 US disclosed
WO-2015200709-A1 HISTONE DEMETHYLASE INHIBITORS Quanticel Pharmaceuticals, Inc. (US) 2015-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150376169-A1 HISTONE DEMETHYLASE INHIBITORS KDM1B, KDM6A, KDM1A KDM4C 16/4885KDM6B 4/4885KDM4A 12/4885
US-20160107995-A1 HISTONE DEMETHYLASE INHIBITORS KDM1B, KDM6A, KDM1A KDM4C 16/4885KDM6B 4/4885KDM4A 12/4885
US-10106534-B2 Histone demethylase inhibitors KDM1B, KDM6A, KDM1A KDM4C 16/4885KDM6B 4/4885KDM4A 12/4885
US-10385047-B2 Histone demethylase inhibitors KDM1B, KDM6A, KDM1A KDM4C 16/4885KDM6B 4/4885KDM4A 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.